Hyperfine Inc. Class A (HYPR)
NASDAQ: HYPRHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HYPR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $57.96M
- EPS (TTM)
- -$0.29
- Dividend yield
- None
- 52-week range
- 0.488 – 1.94
- Day range
- 0.4881 – 0.55
- Volume / Avg
- 1.24M / 760.76K
- Beta
- —
- Shares outstanding
- 90.99M
52-week range
HYPR stock today
On Nov 20, HYPR ended the session at $0.5465, adding $0.0224 (4.27%), versus the S&P 500's 3.70% decline. Shares are 71.8% below their 52-week high of $1.94, set on May 1, 2026 and 12.0% above the 52-week low of $0.488, near the bottom of the past year's range. HYPR is down 44.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 48.0%.
Hyperfine has posted a net loss over the last twelve months (EPS of -$0.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Hyperfine
Company profileHyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Ms. Maria Degois-Sainz
- Headquarters
- Guilford, CT
- Employees
- 102
- IPO year
- 2021
- Website
- hyperfinemri.com
Financial highlights
Full financialsIn fiscal 2025, Hyperfine generated $13.6 million in revenue, up 5.2% from fiscal 2024, its 5th consecutive year of revenue growth. Hyperfine reported a net loss of $35.6 million, compared with a loss of $40.7 million a year earlier. Gross margin was 49.8% (up from 45.7%) and operating margin -273.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $13.56M | $12.89M | $11.03M | $6.81M | $1.50M |
| Growth | +5.22% | +16.84% | +61.90% | +355.48% | +408.84% |
| Net income | $-35.57M | $-40.72M | $-44.24M | $-44.24M | $-64.85M |
| EPS (diluted) | $-0.43 | $-0.56 | $-0.62 | $-1.04 | $-17.57 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$2.03+271.45%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.06 vs $-0.08
- Surprise
- +25.00%
HYPR news
All HYPR newsHyperfine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs HYPR |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs HYPR |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs HYPR |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs HYPR |
| QTIQT Imaging Holdings Inc. | 1.92 | +2.67% | $28.21M | vs HYPR |
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs HYPR |
| STXSStereotaxis Inc. | 0.9422 | -6.71% | $95.03M | vs HYPR |
| VANIVivani Medical Inc. | 1.14 | +4.59% | $102.83M | vs HYPR |
Indexes, lists and sector
Hyperfine stock FAQ
What is Hyperfine's stock price today?
HYPR last traded at $0.5465 as of Nov 20, 4:00 PM EST, up 4.27% on the day. Prices are delayed at least 15 minutes.
Who is Hyperfine's CEO?
Ms. Maria Degois-Sainz is the chief executive officer of Hyperfine Inc. Class A, which has about 102 employees.
What is the HYPR 52-week high?
The 52-week high for HYPR is $1.94 and the 52-week low is $0.488. The stock is currently 71.8% below its high.